维普期刊资源整合服务平台（V6.5）

维普中文期刊产品整合服务

1篇 您的检索式：作者名="Archie Brown"

选中清除导出查看参考文献查看引证文献引用追踪共1页首页上一页第1页下一页末页 /1 跳转

		题名	作者	年代	出处	被引量
	1	WNK-SPAK/OSR1-NCC kinase signaling pathway as a novel target for the treatment of salt-sensitive hypertension显示文摘Hypertension is the most prevalent health condition worldwide,affecting~1 billion people.Gordon’s syndrome is a form of secondary hypertension that can arise due to a number of possible mutations in key genes that encode proteins in a pathway containing the With No Lysine[K](WNK)and its downstream target kinases,SPS/Ste20-related proline-alanine-rich kinase(SPAK)and oxidative stress responsive kinase 1(OSR1).This pathway regulates the activity of the thiazide-sensitive sodium chloride cotransporter(NCC),which is responsible for NaCl reabsorption in the distal nephron.Therefore,mutations in genes encoding proteins that regulate the NCC proteins disrupt ion homeostasis and cause hypertension by increasing NaCl reabsorption.Thiazide diuretics are currently the main treatment option for Gordon’s syndrome.However,they have a number of side effects,and chronic usage can lead to compensatory adaptations in the nephron that counteract their action.Therefore,recent research has focused on developing novel inhibitory molecules that inhibit components of the WNK-SPAK/OSR1-NCC pathway,thereby reducing NaCl reabsorption and restoring normal blood pressure.In this review we provide an overview of the currently reported molecular inhibitors of the WNK-SPAK/OSR1-NCC pathway and discuss their potential as treatment options for Gordon’s syndrome.	Archie Brown Nur Farah Meor Azlan Zhijuan Wu Jinwei Zhang	2021	Acta Pharmacologica Sinica2021，42，4：	2

返回顶部每页显示：

共1页首页上一页第1页下一页末页 /1 跳转

goolge学术搜索-维普

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1　渝公网安备 50019002500403号　违法和不良信息举报中心

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费